HI-207

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581043

CAS#: 244268-79-9

Description: HI-207 is a non-nucleoside reverse transcriptase inhibitor.


Chemical Structure

img
HI-207
CAS# 244268-79-9

Theoretical Analysis

MedKoo Cat#: 581043
Name: HI-207
CAS#: 244268-79-9
Chemical Formula: C13H14N4S
Exact Mass: 258.09
Molecular Weight: 258.340
Elemental Analysis: C, 60.44; H, 5.46; N, 21.69; S, 12.41

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: HI-207; HI 207; HI207.

IUPAC/Chemical Name: 1-Pyridin-2-yl-3-(2-pyridin-2-yl-ethyl)-thiourea

InChi Key: UDVAVGGOTLVVIZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H14N4S/c18-13(17-12-6-2-4-9-15-12)16-10-7-11-5-1-3-8-14-11/h1-6,8-9H,7,10H2,(H2,15,16,17,18)

SMILES Code: S=C(NCCC1=NC=CC=C1)NC2=NC=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 258.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nii-Trebi NI, Brandful JAM, Ibe S, Sugiura W, Barnor JS, Bampoh PO, Yamaoka S, Matano T, Yoshimura K, Ishikawa K, Ampofo WK. Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana. J Med Microbiol. 2017 Oct 25. doi: 10.1099/jmm.0.000621. [Epub ahead of print] PubMed PMID: 29068286.

2: Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017 Feb 22;8:6-14. doi: 10.1016/j.jcte.2017.01.004. eCollection 2017 Jun. Review. PubMed PMID: 29067253; PubMed Central PMCID: PMC5651339.

3: Viciana P. Rilpivirine: The Key for Long-term Success. AIDS Rev. 2017 Oct-Dec;19(3):156-166. PubMed PMID: 29066858.

4: Bangirana P, Ruel TD, Boivin MJ, Pillai SK, Giron LB, Sikorskii A, Banik A, Achan J. Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy. J Int AIDS Soc. 2017 Oct;20(2). doi: 10.1002/jia2.25015. PubMed PMID: 29052340.

5: Kundro MA, Viloria GA, Toibaro JJ, Losso MH. Antiretroviral therapy and arterial elasticity in HIV-infected patients. Medicina (B Aires). 2017;77(5):365-369. PubMed PMID: 29044011.

6: Tres F, Hall SD, Mohutsky MA, Taylor LS. Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence Techniques. J Pharm Sci. 2017 Oct 11. pii: S0022-3549(17)30691-3. doi: 10.1016/j.xphs.2017.10.002. [Epub ahead of print] PubMed PMID: 29031978.

7: Jordan MR, Penazzato M, Cournil A, Vubil A, Jani I, Hunt G, Carmona S, Maphalala G, Mthethwa N, Watera C, Kaleebu P, Chakanyuka Musanhu C, Mtapuri-Zinyowera S, Dzangare J, Peeters M, Yang C, Parkin N, Bertagnolio S. HIV drug resistance in African infants and young children newly diagnosed with HIV: a multicounty analysis. Clin Infect Dis. 2017 Aug 8. doi: 10.1093/cid/cix698. [Epub ahead of print] PubMed PMID: 29020335.

8: Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents. Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198. [Epub ahead of print] PubMed PMID: 28994660.

9: Memarnejadian A, Gouklani H, Mohammadi S, Moosazadeh M, Choi J. Prevalence of HIV-1 pre-treatment drug resistance in a southern province of Iran, 2016-2017. Arch Virol. 2017 Oct 5. doi: 10.1007/s00705-017-3572-1. [Epub ahead of print] PubMed PMID: 28983848.

10: Gong T, Zhang W, Parniak MA, Graebing PW, Moncla B, Gupta P, Empey KM, Rohan LC. Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention. J Pharm Innov. 2017 Jun;12(2):142-154. doi: 10.1007/s12247-017-9274-0. Epub 2017 Mar 3. PubMed PMID: 28983328; PubMed Central PMCID: PMC5624728.

11: Inzaule SC, Osi SJ, Akinbiyi G, Emeka A, Khamofu H, Mpazanje R, Ilesanmi O, Ndembi N, Odafe S, Sigaloff KCE, Rinke de Wit TF, Akanmu S. High prevalence of HIV drug resistance among newly diagnosed infants aged <18 months: results from a nationwide surveillance in Nigeria. J Acquir Immune Defic Syndr. 2017 Sep 25. doi: 10.1097/QAI.0000000000001553. [Epub ahead of print] PubMed PMID: 28961680.

12: Pessôa R, Sanabani SS. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors. PLoS One. 2017 Sep 27;12(9):e0185559. doi: 10.1371/journal.pone.0185559. eCollection 2017. PubMed PMID: 28953964; PubMed Central PMCID: PMC5617215.

13: Al-Salama ZT. Elsulfavirine: First Global Approval. Drugs. 2017 Sep 23. doi: 10.1007/s40265-017-0820-3. [Epub ahead of print] PubMed PMID: 28940154.

14: Santoro MM, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197. [Epub ahead of print] PubMed PMID: 28935850.

15: Contreras-Galindo RA, Dube D, Fujinaga K, Kaplan MH, Markovitz DM. Susceptibility of Human Endogenous Retrovirus Type-K to Reverse Transcriptase Inhibitors. J Virol. 2017 Sep 20. pii: JVI.01309-17. doi: 10.1128/JVI.01309-17. [Epub ahead of print] PubMed PMID: 28931682.

16: Sharaf NG, Xi Z, Ishima R, Gronenborn AM. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site. Proteins. 2017 Sep 14. doi: 10.1002/prot.25383. [Epub ahead of print] PubMed PMID: 28905420.

17: Kan W, Teng T, Liang S, Ma Y, Tang H, Zuohela T, Sun G, He C, Wall KM, Marconi VC, Liao L, Leng X, Liu P, Ruan Y, Xing H, Shao Y. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study. BMJ Open. 2017 Sep 7;7(9):e016012. doi: 10.1136/bmjopen-2017-016012. PubMed PMID: 28882911; PubMed Central PMCID: PMC5595192.

18: Jones E, Mazirka P, McNurlan MA, Darras F, Gelato MC, Caso G. Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes. World J Virol. 2017 Aug 12;6(3):53-58. doi: 10.5501/wjv.v6.i3.53. PubMed PMID: 28868243; PubMed Central PMCID: PMC5561499.

19: Corona A, Onnis V, Deplano A, Bianco G, Demurtas M, Distinto S, Cheng YC, Alcaro S, Esposito F, Tramontano E. Design, synthesis and antiviral evaluation of novel heteroarylcarbothioamide derivatives as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and RDDP functions. Pathog Dis. 2017 Aug 31;75(6). doi: 10.1093/femspd/ftx078. PubMed PMID: 28859311.

20: Bastida C, Grau A, Márquez M, Tuset M, De Lazzari E, Martínez E, Gatell JM. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm Hosp. 2017 Sep 1;41(5):618-624. doi: 10.7399/fh.10778. PubMed PMID: 28847251.